{"commentary":{"count":20,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":10,"x_thread":8,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02194842\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PEACE III","nct_id":"NCT02194842","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=peace-iii-nct02194842. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"PEACE III","arms":[{"description":"Enzalutamide will be given at a dose of 160 mg daily","label":"Enzalutamide","type":"ACTIVE_COMPARATOR"},{"description":"Ra223 will be administered 55kBq/kg standard dose monthly for 6 months and given in combination with enzalutamide at a dose of 160 mg daily.","label":"Enzalutamide and Ra223","type":"EXPERIMENTAL"}],"collaborators":["Bayer","Astellas Pharma Europe Ltd.","UNICANCER","Canadian Urologic Oncology Group","Latin American Cooperative Oncology Group","Cancer Trials Ireland"],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":446,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ra223","type":"DRUG"},{"name":"Enzalutamide","type":"DRUG"}],"last_update":"2025-09-19","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","official_title":"A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-02-19","type":"ACTUAL"},"primary_outcomes":[{"measure":"radiological progression-free survival","timeFrame":"46 months after first patient entry"},{"measure":"progression-free survival per Blinded Independent Central Review (PFS1B)","timeFrame":"96 months after first patient entry"}],"references":[{"citation":"Tombal B, Saad F, Gallardo E, Soares A, Loriot Y, McDermott R, Briers E, Lagstrom M, Coens C, Poncet C, Fournier B, Gillessen S. A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases. Future Oncol. 2025 Dec;21(30):3845-3858. doi: 10.1080/14796694.2025.2592722. Epub 2025 Nov 28.","pmid":"41313045","type":"DERIVED"},{"citation":"Gillessen S, Tombal B, Turco F, Choudhury A, Rodriguez-Vida A, Gallardo E, Velho PI, Nole F, Cruz F, Loriot Y, McDermott R, Roumeguere T, Daugaard G, Yamamura R, Bompas E, Maroto P, Polo MH, da Trindade KM, Preto DD, Skoneczna I, Lecouvet F, Coens C, Fournier B, Saad F. Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis. Eur Urol. 2025 Mar;87(3):285-288. doi: 10.1016/j.eururo.2024.11.027. Epub 2025 Jan 17.","pmid":"39827019","type":"DERIVED"}],"start_date":{"date":"2015-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase III Radium 223 mCRPC-PEACE III","url":"https://clinicaltrials.gov/study/NCT02194842"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/peace-iii-nct02194842"}